{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:22:51Z","timestamp":1792498971696,"version":"4.5.0"},"reference-count":175,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"abstract":"<jats:sec id=\"ab-jsc260010-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>SARS-CoV-2 remains a substantial cause of respiratory illness, morbidity, and mortality. Evidence to date has demonstrated that COVID-19 vaccines reduce the risk of severe disease, including hospitalization and death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jsc260010-2\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This systematic review identifies and summarizes newly published studies reporting on the effectiveness and safety of COVID-19 vaccines and COVID-19 epidemiology in the US.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jsc260010-3\">\n                    <jats:title>Evidence Review<\/jats:title>\n                    <jats:p>Cochrane Central Register of Controlled Trials, PubMed\/MEDLINE, Embase, and Scopus were searched from August 1, 2025, through June 29, 2026. Studies were eligible if they reported on the effectiveness, efficacy, or safety of a US-licensed COVID-19 vaccine or SARS-CoV-2 epidemiology in the US.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jsc260010-4\">\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>From 11\u202f829 identified references, 155 publications were eligible (15 randomized clinical trials, 84 observational studies with a comparator group, 38 product safety studies without a comparator group [single group], and 18 descriptive studies of disease burden). Consistent with prior evidence, studies reported that updated COVID-19 vaccines were associated with a reduction in the risk of hospitalization among both older adults (\u226565 years; vaccine effectiveness [VE], 53.0%; 95% CI, 37.0%-65.0%; 2025-2026 season) and adults (18-64 years; VE, 54.0%; 95% CI, 1.0%-78.0%; 2024-2025 season). Maternal vaccination was associated with reduced risk of COVID-19\u2013associated emergency department\/urgent care encounters among individuals vaccinated (VE, 58.0%; 95% CI, 24.0%-77.0%) and with fewer COVID-19\u2013related hospital contacts in the first 2 months of life among infants born subsequently (VE range, 50.0%-54.0%), regardless of trimester of vaccination. Vaccination was also associated with a significant reduction in COVID-19\u2013related pediatric emergency department visits (9 months to 4 years; VE, 76.0%; 95% CI, 58.0%-87.0%). Vaccination was associated with a reduced risk of critical COVID-19 illness (intensive care unit admission or death) in immunocompromised adults (VE range, 32.0%-53.0%, depending on condition and other factors). Health care personnel who received 3 to 5 vaccine doses were less likely to develop laboratory-confirmed COVID-19 illness (VE, 41.0%; 95% CI, 34.0%-47.0%) and postacute COVID-19 symptoms (VE, 57.0%; 95% CI, 46.0%-66.0%) compared with those who received only 2 doses. Across adverse events of special interest (eg, stroke, thrombosis, myocarditis), safety profiles were consistent with those of previous reviews. No identified studies conducted under the updated guidance on extended dosing intervals for the primary series reported an increased risk of myocarditis or pericarditis. No new safety signals were reported in the recently published studies eligible for this updated review of US-licensed COVID-19 vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jsc260010-5\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>COVID-19 vaccines were consistently associated with a reduction in the risk of hospitalization and other outcomes, including among individuals at high risk of severe COVID-19, such as infants, and those who were pregnant. No new safety concerns were identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2026.18191","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:30:20Z","timestamp":1788359420000},"source":"Crossref","is-referenced-by-count":2,"title":["COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season"],"prefix":"10.1001","author":[{"given":"Rachel A.","family":"Lipson","sequence":"first","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Senerth","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Watson","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harseerat","family":"Saini","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Falk","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Tangri","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyedeh Mahsa","family":"Sheikholeslamian","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapeena","family":"Sivakumaran","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifeoluwa","family":"Babatunde","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Wharton","sequence":"additional","affiliation":[{"name":"Oakwood Consulting, LLC, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela K.","family":"Ulrich","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah E.","family":"Moat","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare J.","family":"Stoddart","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise J.","family":"Holmes","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle P.","family":"Walensky","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine and Infectious Disease, Massachusetts General Hospital, Harvard Medical School, Boston"},{"name":"Vaccine Integrity Project, Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E.","family":"Basta","sequence":"additional","affiliation":[{"name":"Vaccine Integrity Project, Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis"},{"name":"Division of Epidemiology, Biostatistics, and Occupational Health, School of Population and Global Health, Faculty of Medicine and Health Sciences, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"},{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"6","key":"jsc260010r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.25152","article-title":"Interim estimated effectiveness of 2025-2026 COVID-19 vaccines in adults using a test-negative design.","volume":"9","author":"Wiegand","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"22","key":"jsc260010r5","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMsa2514268","article-title":"Updated evidence for Covid-19, RSV, and influenza vaccines for 2025-2026.","volume":"393","author":"Scott","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"jsc260010r7","doi-asserted-by":"publisher","first-page":"728","DOI":"10.7326\/ANNALS-25-05026","article-title":"COVID-19 vaccines for 2025-2026 in adults who are not pregnant or immunocompromised: rapid practice points from the American College of Physicians.","volume":"179","author":"Qaseem","year":"2026","journal-title":"Ann Intern Med"},{"key":"jsc260010r8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciag114","article-title":"IDSA 2025 guidelines on the use of vaccines for the prevention of seasonal COVID-19, influenza, and RSV infections in immunocompromised patients.","author":"Nellore","journal-title":"Clin Infect Dis"},{"issue":"5","key":"jsc260010r9","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-073924","article-title":"Recommendations for COVID-19 vaccines in infants, children, and adolescents: policy statement.","volume":"156","author":"Committee on Infectious Diseases","year":"2025","journal-title":"Pediatrics"},{"issue":"37","key":"jsc260010r10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.15585\/mmwr.mm7337e2","article-title":"Use of COVID-19 vaccines for persons aged =6 months: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024-2025.","volume":"73","author":"Panagiotakopoulos","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"71","key":"jsc260010r11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"jsc260010r14","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"jsc260010r15","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"jsc260010r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127960","article-title":"Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants.","volume":"69","author":"Grassi","year":"2026","journal-title":"Vaccine"},{"issue":"4","key":"jsc260010r17","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofag139","article-title":"Evaluation of cardiac troponin levels in individuals aged 12-30 years following mRNA-1273 vaccination: results from a randomized placebo-controlled trial.","volume":"13","author":"Pfeiffer","year":"2026","journal-title":"Open Forum Infect Dis"},{"key":"jsc260010r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2026.108466","article-title":"Immunogenicity, reactogenicity, and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults =75 years (EU-COVAT-1-AGED)\u2014final report.","volume":"165","author":"Stemler","year":"2026","journal-title":"Int J Infect Dis"},{"issue":"1","key":"jsc260010r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106663","article-title":"Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): a randomised controlled non-inferiority trial.","volume":"92","author":"Kelly","year":"2026","journal-title":"J Infect"},{"key":"jsc260010r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.128130","article-title":"Safety and immunogenicity of BNT162b2 vaccine in children with acute leukaemia: results and perspectives of an open-label, two-centre, phase 1\/2 trial with dose finding study.","volume":"74","author":"Alby-Laurent","year":"2026","journal-title":"Vaccine"},{"issue":"1","key":"jsc260010r21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.191266","article-title":"Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial.","volume":"11","author":"Mackay","year":"2025","journal-title":"JCI Insight"},{"issue":"1","key":"jsc260010r22","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2589644","article-title":"Phase 1\/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults.","volume":"22","author":"Rudman Spergel","year":"2026","journal-title":"Hum Vaccin Immunother"},{"key":"jsc260010r23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1789248","article-title":"Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial.","volume":"17","author":"Batmunkh","year":"2026","journal-title":"Front Immunol"},{"issue":"4","key":"jsc260010r24","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/vaccines14040350","article-title":"A study to investigate the safety and immunogenicity of monovalent Omicron LP.8.1-adapted BNT162b2 COVID-19 vaccine in adults = 65 years of age and high-risk adults 18-64 years of age (preliminary results).","volume":"14","author":"Dadhe","year":"2026","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"jsc260010r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2026.106784","article-title":"Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial.","volume":"93","author":"Harris","year":"2026","journal-title":"J Infect"},{"key":"jsc260010r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128304","article-title":"A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial.","volume":"76","author":"Oyedele","year":"2026","journal-title":"Vaccine"},{"issue":"5","key":"jsc260010r27","doi-asserted-by":"publisher","first-page":"e1083","DOI":"10.1093\/cid\/ciag026","article-title":"Safety and immunogenicity of a fourth dose of Omicron BA.1-adapted BNT162b2 COVID-19 vaccines in adults 18-55 years old.","volume":"82","author":"Winokur","year":"2026","journal-title":"Clin Infect Dis"},{"key":"jsc260010r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127749","article-title":"Comparing the immunogenicity of intradermal and intramuscular vaccination of elderly with BNT162b2 XBB.1.5: an equivalent dose study.","volume":"64","author":"van Beek","year":"2025","journal-title":"Vaccine"},{"issue":"3","key":"jsc260010r29","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/S2352-3018(25)00275-9","article-title":"Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS\u2013protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa: a phase 2a randomised, observer-blind trial.","volume":"13","author":"Govender","year":"2026","journal-title":"Lancet HIV"},{"key":"jsc260010r30","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciag344","article-title":"Immunogenicity and safety of co-administration of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine and a COVID-19 mRNA vaccine in adults aged =50 years: a phase 3, randomized, non-inferiority trial.","author":"Bonten","journal-title":"Clin Infect Dis"},{"key":"jsc260010r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127870","article-title":"Effectiveness of spring 2024 (XBB.1.5) and autumn 2024 (JN.1) COVID-19 vaccination against hospitalisation in England.","volume":"67","author":"Abdul Aziz","year":"2025","journal-title":"Vaccine"},{"issue":"1","key":"jsc260010r32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/infdis\/jiag137","article-title":"2024-2025 COVID-19 mRNA vaccine effectiveness against severe disease.","volume":"234","author":"Jayawardena","year":"2026","journal-title":"J Infect Dis"},{"issue":"2","key":"jsc260010r33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.57415","article-title":"Estimated effectiveness of 2024-2025 COVID-19 vaccination against severe COVID-19.","volume":"9","author":"Ma","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"2","key":"jsc260010r34","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofag019","article-title":"Effectiveness and durability of the BNT162b2 KP.2 vaccine against COVID-19 hospitalization and emergency department or urgent care encounters in US adults.","volume":"13","author":"Tartof","year":"2026","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"jsc260010r35","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s40121-026-01395-4","article-title":"Interim effectiveness of 2025-2026 mRNA-1283 and BNT162b2 COVID-19 vaccines against COVID-19\u2013related outcomes among adults aged?=?65 years in the United States.","volume":"15","author":"Vicic","year":"2026","journal-title":"Infect Dis Ther"},{"issue":"3","key":"jsc260010r36","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s40121-025-01292-2","article-title":"Evaluating the effectiveness of 2024-2025 seasonal mRNA-1273 vaccination against COVID-19\u2013related hospitalizations and medically attended COVID-19 among adults aged = 18 years in the United States: an observational matched cohort study.","volume":"15","author":"Vicic","year":"2026","journal-title":"Infect Dis Ther"},{"issue":"8","key":"jsc260010r37","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1001\/jamainternmed.2026.1936","article-title":"Estimated effectiveness of 2024-2025 COVID-19 vaccines in adults.","volume":"186","author":"Wiegand","year":"2026","journal-title":"JAMA Intern Med"},{"issue":"12","key":"jsc260010r38","doi-asserted-by":"publisher","DOI":"10.1111\/irv.70198","article-title":"Effectiveness of the 2023 autumn XBB.1.5 COVID-19 booster during summer 2024 in the EU\/EEA: a VEBIS Electronic Health Record Network study.","volume":"19","author":"Humphreys","year":"2025","journal-title":"Influenza Other Respir Viruses"},{"key":"jsc260010r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128276","article-title":"Effectiveness of bivalent BA.1 mRNA booster vaccines during the autumn 2022 COVID-19 booster programme in adults aged 50+ in England: observational matched cohort study using OpenSAFELY.","volume":"76","author":"Madley-Dowd","year":"2026","journal-title":"Vaccine"},{"issue":"9","key":"jsc260010r40","doi-asserted-by":"publisher","DOI":"10.1111\/irv.70163","article-title":"Effectiveness and impact of autumn 2023 COVID-19 vaccination in preventing hospitalizations in Navarre, Spain, October 2023 to September 2024.","volume":"19","author":"Mart\u00ednez-Baz","year":"2025","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"jsc260010r41","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1080\/14760584.2025.2576243","article-title":"Effectiveness of the autumnal COVID-19 vaccine dose during the winter and summer waves of the 2023\/24 season in Spain.","volume":"24","author":"Rojas-Benedicto","year":"2025","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"jsc260010r42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0342382","article-title":"Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: a test-negative case-control study using the id.DRIVE platform.","volume":"21","author":"Volkman","year":"2026","journal-title":"PLoS One"},{"key":"jsc260010r43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2025.100737","article-title":"Effectiveness of 2023-2024 mRNA-1273 XBB.1.5 vaccine against COVID-19 associated hospitalizations and medically attended COVID-19 in the United States.","volume":"27","author":"Zheng","year":"2025","journal-title":"Vaccine X"},{"issue":"16","key":"jsc260010r44","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa2510226","article-title":"Association of 2024-2025 Covid-19 vaccine with Covid-19 outcomes in US veterans.","volume":"393","author":"Cai","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"jsc260010r45","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41467-025-67796-0","article-title":"Effectiveness of the 2024-2025 KP.2 COVID-19 vaccines in the United States during long-term follow-up.","volume":"17","author":"Ioannou","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"jsc260010r46","doi-asserted-by":"publisher","first-page":"6912","DOI":"10.1038\/s41467-026-73798-3","article-title":"BNT162b2 LP.8.1 early vaccine effectiveness against COVID-19 emergency department, urgent care, and outpatient visits.","volume":"17","author":"Appaneal","year":"2026","journal-title":"Nat Commun"},{"issue":"3","key":"jsc260010r47","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1093\/cid\/ciae405","article-title":"Effectiveness of updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination against SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineage hospitalization and a comparison of clinical severity\u2014IVY Network, 26 Hospitals, 18 October 2023-9 March 2024.","volume":"82","author":"Ma","year":"2026","journal-title":"Clin Infect Dis"},{"issue":"15","key":"jsc260010r48","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2026.31.15.2500672","article-title":"Clinical and economic benefits of seasonal COVID-19 vaccination in Germany: results from the ROUTINE-COV19 study, September 2022 to March 2024.","volume":"31","author":"Schmetz","year":"2026","journal-title":"Euro Surveill"},{"key":"jsc260010r49","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-026-03650-z","article-title":"Comparative effectiveness of mRNA-1273 versus protein-based NVX-CoV2705 vaccination on COVID-19\u2013related outcomes among insured adults in the United States during 2024-2025: a retrospective matched cohort study.","author":"Wilson","journal-title":"Adv Ther"},{"issue":"8","key":"jsc260010r50","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2025.105183","article-title":"Protection conferred by the Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccine to patients hospitalized with COVID-19 in Greece in 2023-2024.","volume":"55","author":"Maltezou","year":"2025","journal-title":"Infect Dis Now"},{"issue":"4","key":"jsc260010r51","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/AOG.0000000000006145","article-title":"Effectiveness of 2023-2024 coronavirus disease 2019 (COVID-19) vaccines in pregnant women.","volume":"147","author":"Ciesla","year":"2026","journal-title":"Obstet Gynecol"},{"issue":"4","key":"jsc260010r52","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-073661","article-title":"COVID-19 mRNA vaccination in pregnancy and risk of infection in early childhood.","volume":"157","author":"Eide","year":"2026","journal-title":"Pediatrics"},{"issue":"40","key":"jsc260010r53","doi-asserted-by":"publisher","first-page":"607","DOI":"10.15585\/mmwr.mm7440a1","article-title":"Effectiveness of 2024-2025 COVID-19 vaccines in children in the United States\u2014VISION, August 29, 2024-September 2, 2025.","volume":"74","author":"Irving","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"jsc260010r54","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3390\/microorganisms14040883","article-title":"Effectiveness of COVID-19 vaccine boosters in children across pandemic and endemic periods.","volume":"14","author":"Oliveira","year":"2026","journal-title":"Microorganisms"},{"key":"jsc260010r55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2025.114778","article-title":"BNT162b2 XBB.1.5-adapted single dose vaccine uptake and effectiveness in children aged 5-17 years using linked claims and vaccine registries in California and Louisiana.","volume":"286","author":"Andersen","year":"2025","journal-title":"J Pediatr"},{"issue":"11","key":"jsc260010r56","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70239","article-title":"Impact and effectiveness of COVID-19 mRNA vaccination against COVID-19 hospitalisation in paediatrics: a cohort study using two linked data sources in Spain.","volume":"34","author":"Castillo-Cano","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"jsc260010r57","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1097\/INF.0000000000005109","article-title":"Effectiveness and safety of COVID-19 mRNA vaccines in children 6-17 years old: a population-based study in Madrid.","volume":"45","author":"Hern\u00e1n","year":"2026","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"jsc260010r58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1542\/peds.2025-073212","article-title":"Effectiveness of 2023-2024 COVID-19 vaccines in children in the United States.","volume":"156","author":"Irving","year":"2025","journal-title":"Pediatrics"},{"issue":"6","key":"jsc260010r59","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1053\/j.ajkd.2025.07.012","article-title":"Effectiveness of bivalent mRNA COVID-19 vaccine among adults with kidney failure receiving dialysis: a cohort study from the Centers for Medicare and Medicaid Services.","volume":"86","author":"Payne","year":"2025","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"jsc260010r60","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/15269248251383951","article-title":"Coronavirus disease 2019 (COVID-19) vaccination coverage and effectiveness among pediatric transplant recipients.","volume":"35","author":"Cohen","year":"2025","journal-title":"Prog Transplant"},{"issue":"6","key":"jsc260010r61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2026.106753","article-title":"Effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 reinfection in patients with cancer: evidence from a nationwide target trial emulation.","volume":"92","author":"Kim","year":"2026","journal-title":"J Infect"},{"issue":"3","key":"jsc260010r62","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.1093\/cid\/ciaf549","article-title":"Effectiveness of COVID-19 vaccination and prior infections to reduce long COVID risk during the pre-Omicron and Omicron periods.","volume":"82","author":"Carazo","year":"2026","journal-title":"Clin Infect Dis"},{"issue":"1","key":"jsc260010r63","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1186\/s12916-025-04503-2","article-title":"Hybrid, infection- and vaccination-induced protection against laboratory-confirmed SARS-CoV-2 infection in a European multi-centre prospective cohort of healthcare workers, 2021-2024.","volume":"23","author":"Rojas-Castro","year":"2025","journal-title":"BMC Med"},{"issue":"21","key":"jsc260010r64","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.125.044546","article-title":"COVID-19 vaccination and cardiovascular outcomes in older adults with coronary artery disease and heart failure: insights from a large propensity-matched cohort study.","volume":"14","author":"Akbar","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"jsc260010r65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2026.100791","article-title":"Post\u2013emergency use authorization active safety surveillance study of the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine in the Veterans Affairs health system: findings from a three-year, comprehensive safety assessment program.","volume":"29","author":"Asomaning","year":"2026","journal-title":"Vaccine X"},{"issue":"1","key":"jsc260010r66","doi-asserted-by":"publisher","first-page":"10878","DOI":"10.1038\/s41598-026-45261-2","article-title":"Adverse events following SARS-CoV-2 mRNA vaccination in Norwegian adolescents.","volume":"16","author":"Bergstad Larsen","year":"2026","journal-title":"Sci Rep"},{"key":"jsc260010r67","doi-asserted-by":"publisher","DOI":"10.2196\/75094","article-title":"Active surveillance for COVID-19 vaccine safety using sequential analysis in Korea: population-based retrospective observational study.","volume":"12","author":"Jeong","year":"2026","journal-title":"JMIR Public Health Surveill"},{"key":"jsc260010r68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.108289","article-title":"Assessing the association between COVID-19 vaccination and thrombotic thrombocytopenia syndrome (ATTEST study): analyses of English data, 2020-2022.","volume":"164","author":"Ord\u00f3\u00f1ez-Mena","year":"2026","journal-title":"Int J Infect Dis"},{"key":"jsc260010r69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.108050","article-title":"Adverse events associated with COVID-19 vaccination or diagnosis among pregnant and non-pregnant women in the United States, 2021-2022.","volume":"160","author":"Rowe","year":"2025","journal-title":"Int J Infect Dis"},{"issue":"8","key":"jsc260010r70","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.7326\/ANNALS-26-00217","article-title":"Adverse events after same-day COVID-19 and influenza vaccination versus influenza vaccination alone: a target trial emulation.","volume":"179","author":"Xie","year":"2026","journal-title":"Ann Intern Med"},{"issue":"17","key":"jsc260010r71","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1038\/s41433-025-04050-3","article-title":"Ophthalmic complications associated with COVID-19: a large US national database analysis.","volume":"39","author":"Azar","year":"2025","journal-title":"Eye (Lond)"},{"key":"jsc260010r72","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1637870","article-title":"Comparison of the rates of emergent otologic adverse events following mRNA COVID-19 versus influenza vaccination: a matched cohort analysis.","volume":"16","author":"Munjal","year":"2025","journal-title":"Front Neurol"},{"issue":"1","key":"jsc260010r73","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2560172","article-title":"Safety of co-administration of COVID-19 and seasonal influenza vaccines in individuals with autoimmune diseases from the Canadian National Vaccine Safety Network.","volume":"21","author":"Soe","year":"2025","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"jsc260010r74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004924","article-title":"Association between COVID-19 vaccination and sudden death in apparently healthy younger individuals: a population-based case-control study.","volume":"23","author":"Abdel-Qadir","year":"2026","journal-title":"PLoS Med"},{"key":"jsc260010r75","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2026.101216","article-title":"No excess risk of death or multimorbidity following hemorrhagic stroke after mRNA vaccination compared with historical cases: a population-based cohort study.","volume":"53","author":"Song","year":"2026","journal-title":"Brain Behav Immun Health"},{"issue":"1","key":"jsc260010r76","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2026.2664323","article-title":"Safety of COVID-19 and influenza vaccines in children and adolescents with immunocompromised or autoimmune conditions: findings from the Canadian National Vaccine Safety (CANVAS) network.","volume":"22","author":"Turner","year":"2026","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"jsc260010r77","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70207","article-title":"Safety of BNT162b2 mRNA COVID-19 vaccine batches: a nationwide cohort study.","volume":"34","author":"Hviid","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"jsc260010r78","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128630","article-title":"mRNA COVID-19 vaccine safety in adults from the Canadian National Vaccine Safety Network.","volume":"84","author":"Muller","year":"2026","journal-title":"Vaccine"},{"issue":"5","key":"jsc260010r79","doi-asserted-by":"publisher","first-page":"118","DOI":"10.47836\/mjmhs.21.5.15","article-title":"Assessment of allergic reaction of Covid-19 vaccination among Malaysian adults: a cross-sectional study.","volume":"21","author":"Rauf","year":"2025","journal-title":"Malays J Med Health Sci"},{"issue":"5","key":"jsc260010r80","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/idr17050108","article-title":"Sex, age, and COVID-19 vaccine characteristics associated with adverse events after vaccination and severity: a retrospective analysis.","volume":"17","author":"Rodr\u00edguez-Vidales","year":"2025","journal-title":"Infect Dis Rep"},{"issue":"1","key":"jsc260010r81","doi-asserted-by":"publisher","first-page":"33183","DOI":"10.1038\/s41598-025-12690-4","article-title":"Adverse effects and SARS-CoV-2 infection after COVID-19 vaccination among the vaccinated people of Bangabandhu Sheikh Mujib Medical University Hospital in Dhaka, Bangladesh: a pilot study.","volume":"15","author":"Sharmin","year":"2025","journal-title":"Sci Rep"},{"key":"jsc260010r82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1815933","article-title":"Long-term immune response to mRNA anti\u2013SARS-CoV-2 vaccination in patients with cancer.","volume":"17","author":"Lobo-Martins","year":"2026","journal-title":"Front Immunol"},{"issue":"12","key":"jsc260010r83","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-106494","article-title":"Safety of COVID-19 vaccines among pregnant individuals in Quebec, Canada: a population-based retrospective cohort study from the Canadian Immunization Research Network.","volume":"15","author":"Kiely","year":"2025","journal-title":"BMJ Open"},{"key":"jsc260010r84","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128474","article-title":"Effectiveness of the COVID-19 messenger RNA vaccine against symptomatic omicron infection in children aged 6 months to 11 years in Japan.","volume":"79","author":"Aizawa","year":"2026","journal-title":"Vaccine"},{"issue":"1","key":"jsc260010r85","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/EDE.0000000000001908","article-title":"OpenSAFELY: effectiveness of COVID-19 vaccination in children and adolescents.","volume":"37","author":"Andrews","year":"2026","journal-title":"Epidemiology"},{"issue":"24","key":"jsc260010r86","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.125.044011","article-title":"Adjudicated cardiovascular events in patients with COVID-19: association with vaccination status and changes over time.","volume":"14","author":"Bikdeli","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"jsc260010r87","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0219-2025","article-title":"Prolonged evaluation of COVID-19 vaccine effectiveness in healthcare workers at a public tertiary hospital: a retrospective cohort study.","volume":"59","author":"Castro","year":"2026","journal-title":"Rev Soc Bras Med Trop"},{"issue":"3","key":"jsc260010r88","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3390\/ph19030477","article-title":"Incidence of Guillain\u2013Barr\u00e9 syndrome following COVID-19 vaccination and SARS-CoV-2 infection: a population-based cohort study using the Valencia Health System Integrated Database (Spain).","volume":"19","author":"Correcher-Mart\u00ednez","year":"2026","journal-title":"Pharmaceuticals"},{"key":"jsc260010r89","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1658340","article-title":"Incidence and severity of SARS-CoV-2 infection and vaccine BNT162 side effects in children and adolescents with Noonan syndrome: a national multicentric study.","volume":"13","author":"Dal Ben","year":"2026","journal-title":"Front Pediatr"},{"key":"jsc260010r90","doi-asserted-by":"publisher","DOI":"10.1155\/ah\/5597825","article-title":"Vaccination and antiviral combination improves resolution time of COVID-19 infection in treated multiple myeloma: a retrospective study.","volume":"2026","author":"Di Cecca","year":"2026","journal-title":"Adv Hematol"},{"issue":"11","key":"jsc260010r91","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1097\/INF.0000000000004954","article-title":"Effectiveness of NVX-CoV2373 and BNT162b2 COVID-19 vaccination in South Korean adolescents.","volume":"44","author":"Gwak","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"jsc260010r92","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127553","article-title":"Adverse drug reactions following SARS-CoV-2 vaccination of 3805 healthcare workers cause substantial sick-leave and are correlated to vaccine regimen, age, sex and serological response.","volume":"62","author":"Lidstr\u00f6m","year":"2025","journal-title":"Vaccine"},{"key":"jsc260010r93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1690495","article-title":"Long-term cellular and humoral responses to SARS-CoV-2 vaccinations in patients with solid malignancies undergoing chemotherapy.","volume":"16","author":"Liu","year":"2026","journal-title":"Front Immunol"},{"key":"jsc260010r94","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128340","article-title":"Risk of spontaneous abortion after mRNA COVID-19 vaccination received just prior to or during pregnancy: complete data from CDC COVID-19 Vaccine Pregnancy Registry.","volume":"76","author":"Madni","year":"2026","journal-title":"Vaccine"},{"key":"jsc260010r95","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2025.1689349","article-title":"Cohort event monitoring of booster COVID-19 vaccine safety using patient-reported outcomes in pregnant women.","volume":"5","author":"Maisonneuve","year":"2025","journal-title":"Front Drug Saf Regul"},{"key":"jsc260010r96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123681","article-title":"Electronic health record analysis reveals no association between COVID-19 vaccines and ischemic stroke.","volume":"478","author":"Makkar","year":"2025","journal-title":"J Neurol Sci"},{"issue":"18","key":"jsc260010r97","doi-asserted-by":"publisher","first-page":"6542","DOI":"10.3390\/jcm14186542","article-title":"Serious adverse drug reactions to COVID-19 vaccines in the pediatric population: a retrospective, cross-sectional study utilizing the Eudravigilance database for the European Economic Area.","volume":"14","author":"Nazar","year":"2025","journal-title":"J Clin Med"},{"issue":"9","key":"jsc260010r98","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40261-025-01466-3","article-title":"Spontaneous reports of adverse reactions with fatal outcomes after COVID-19 vaccination during the national vaccination campaign in Sweden.","volume":"45","author":"Nurminen","year":"2025","journal-title":"Clin Drug Investig"},{"key":"jsc260010r99","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.128167","article-title":"Adverse events post-BNT162b2 vaccination in Japanese children.","volume":"73","author":"Okabe","year":"2026","journal-title":"Vaccine"},{"issue":"2","key":"jsc260010r100","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2025-003584","article-title":"Long-term effects on cardiac function and symptoms in patients with myocarditis following COVID-19 vaccination: the ECHOVID-19 Long-term Study.","volume":"12","author":"Ramadan","year":"2025","journal-title":"Open Heart"},{"issue":"1","key":"jsc260010r101","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1186\/s12879-025-11446-9","article-title":"Assessing SARS-CoV-2 vaccine effectiveness in health workers: a cohort study conducted during the pandemic decline phase in five hospitals, affiliated to Al-Azhar University\u2013Egypt.","volume":"25","author":"Said","year":"2025","journal-title":"BMC Infect Dis"},{"issue":"12","key":"jsc260010r102","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S2352-4642(25)00247-0","article-title":"Vascular and inflammatory diseases after COVID-19 infection and vaccination in children and young people in England: a retrospective, population-based cohort study using linked electronic health records.","volume":"9","author":"Sampri","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"issue":"3","key":"jsc260010r103","doi-asserted-by":"publisher","DOI":"10.1111\/irv.70222","article-title":"Effectiveness of 2024\/25 KP.2 vaccine against outpatient COVID-19 in Canada.","volume":"20","author":"Separovic","year":"2026","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"jsc260010r104","doi-asserted-by":"publisher","first-page":"35179","DOI":"10.1038\/s41598-025-19168-3","article-title":"Effectiveness and durability of a fourth dose of ancestral-strain mRNA vaccines against SARS-CoV-2 infection: a nationwide matched cohort study in Qatar.","volume":"15","author":"Sukik","year":"2025","journal-title":"Sci Rep"},{"issue":"6","key":"jsc260010r105","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1055\/a-2665-2400","article-title":"Venous thrombosis associated with different types of SARS-CoV-2 vaccines in the Netherlands\u2014results of the TERA case-control study.","volume":"126","author":"van Dijk","year":"2026","journal-title":"Thromb Haemost"},{"issue":"4","key":"jsc260010r106","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofag141","article-title":"mRNA and protein subunit COVID-19 vaccine reactogenicity and their relationship to productivity for healthcare workers and first responders.","volume":"13","author":"Yoon","year":"2026","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"jsc260010r107","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2026.103415","article-title":"A comprehensive assessment of the impact of COVID variant and vaccination on venous thromboembolism and mortality.","volume":"10","author":"Soff","year":"2026","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"jsc260010r108","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1001\/jamainternmed.2026.1929","article-title":"COVID-19 vaccine and major adverse cardiovascular events among US veterans.","volume":"186","author":"Cai","year":"2026","journal-title":"JAMA Intern Med"},{"key":"jsc260010r109","doi-asserted-by":"publisher","DOI":"10.1002\/acr.80063","article-title":"Association of vaccination with COVID outcomes in pregnant people with autoimmune diseases: a retrospective national cohort analysis.","author":"Jaferian","year":"2026","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"jsc260010r110","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128786","article-title":"2024\/25 End-of-season KP.2 vaccine effectiveness against COVID-19 hospitalization in older adults: a test-negative study in Quebec, Canada.","volume":"88","author":"Carazo","year":"2026","journal-title":"Vaccine"},{"issue":"1","key":"jsc260010r111","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1186\/s12879-026-13803-8","article-title":"Effectiveness of seasonal mRNA COVID-19 vaccination against post COVID-19 condition between July 2023 and September 2024 among adults aged?=?60?years in Germany: a population-based cohort study.","volume":"26","author":"Perumal","year":"2026","journal-title":"BMC Infect Dis"},{"issue":"6","key":"jsc260010r112","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-014726","article-title":"COVID-19 mRNA vaccination and immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a target trial emulation study.","volume":"14","author":"Chen","year":"2026","journal-title":"J Immunother Cancer"},{"key":"jsc260010r113","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128225","article-title":"Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2-5 years.","volume":"75","author":"Anderson","year":"2026","journal-title":"Vaccine"},{"issue":"11","key":"jsc260010r114","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.113727","article-title":"Cell-based immune anticipation of the omicron variant in SARS-CoV-2 triple-vaccinated cancer patients.","volume":"28","author":"Mairhofer","year":"2025","journal-title":"iScience"},{"issue":"1","key":"jsc260010r115","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s42358-025-00498-9","article-title":"Comparison of the immunogenicity and safety among COVID-19 vaccines ChadOx-1, CoronaVac and BNT162b2 in systemic lupus erythematosus (SLE) patients: a prospective cohort.","volume":"65","author":"Ribeiro","year":"2025","journal-title":"Adv Rheumatol"},{"key":"jsc260010r116","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128208","article-title":"Immunogenicity and safety of a recombinant spike protein COVID vaccine in patients with inflammatory bowel disease and transplant recipient.","volume":"75","author":"Vattoth","year":"2026","journal-title":"Vaccine"},{"key":"jsc260010r117","doi-asserted-by":"publisher","first-page":"49","DOI":"10.33321\/cdi.2025.49.044","article-title":"Surveillance of adverse events following immunisation in Australia annual report, COVID-19 vaccines, 2022.","volume":"49","author":"Huang","year":"2025","journal-title":"Commun Dis Intell (2018)"},{"key":"jsc260010r118","doi-asserted-by":"publisher","first-page":"50","DOI":"10.33321\/cdi.2026.50.002","article-title":"Surveillance of adverse events following immunisation in Australia, 2023.","volume":"50","author":"Nguyen","year":"2026","journal-title":"Commun Dis Intell (2018)"},{"issue":"1","key":"jsc260010r119","doi-asserted-by":"publisher","first-page":"41353","DOI":"10.1038\/s41598-025-25329-1","article-title":"Vaccine side effects after vaccination against COVID-19 in employees at an university hospital in Austria.","volume":"15","author":"Schwarz-Martelanz","year":"2025","journal-title":"Sci Rep"},{"key":"jsc260010r120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2025.100728","article-title":"Phase 2\/3 open-label study on NVX-CoV-2601 (XBB.1.5) vaccine in previously COVID-19 mRNA vaccinated and vaccine-naive, SARS-CoV-2\u2013seropositive participants: a 6-month follow-up.","volume":"27","author":"Alves","year":"2025","journal-title":"Vaccine X"},{"key":"jsc260010r121","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.128164","article-title":"Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: primary analysis report of a phase 3 open-label trial.","volume":"73","author":"Alves","year":"2026","journal-title":"Vaccine"},{"issue":"1","key":"jsc260010r122","doi-asserted-by":"publisher","first-page":"8569","DOI":"10.1038\/s41467-025-63598-6","article-title":"Immunogenicity of fractional and standard dose COVID-19 vaccine boosters among healthy adults in Indonesia: twenty four month follow-up from a randomised controlled trial.","volume":"16","author":"Hart","year":"2025","journal-title":"Nat Commun"},{"issue":"3","key":"jsc260010r123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106576","article-title":"Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial.","volume":"91","author":"Janani","year":"2025","journal-title":"J Infect"},{"key":"jsc260010r124","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2025.100650","article-title":"Immunogenicity and safety of \u201cComvigen\u201d, a bivalent SARS-CoV-2 vaccine, in comparison to Comirnaty bivalent vaccine in Thailand: a phase 2, non-inferiority randomised trial.","volume":"40","author":"Jantarabenjakul","year":"2025","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"1","key":"jsc260010r125","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12985-025-02905-5","article-title":"Acute transverse myelitis and associate vaccine complication in SARS-CoV-2 patients: a retrospective cohort analysis in real-world database.","volume":"22","author":"Lu","year":"2025","journal-title":"Virol J"},{"key":"jsc260010r126","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128725","article-title":"V-safe: summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.","volume":"88","author":"Myers","year":"2026","journal-title":"Vaccine"},{"key":"jsc260010r127","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2026.108844","article-title":"Long-term safety of the Pfizer-BioNTech COVID-19 vaccine: results from the HERO-together study.","volume":"257","author":"O\u2019Brien","year":"2026","journal-title":"Respir Med"},{"issue":"11","key":"jsc260010r129","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0005080","article-title":"Active vaccine safety surveillance: experience from a prospective cohort event monitoring study of COVID-19 vaccines in Kenya.","volume":"5","author":"Odhiambo","year":"2025","journal-title":"PLOS Glob Public Health"},{"issue":"2","key":"jsc260010r130","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1093\/cid\/ciaf455","article-title":"Immunogenicity and safety of the COVID-19 messenger RNA vaccine coadministered with influenza and 23-valent pneumococcal polysaccharide vaccines.","volume":"82","author":"Rezahosseini","year":"2026","journal-title":"Clin Infect Dis"},{"issue":"2","key":"jsc260010r131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2025.100620","article-title":"COVID-19 mRNA revaccination is safe and well tolerated in individuals with previous adverse reactions to the vaccine and\/or long COVID.","volume":"5","author":"Slack","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"2","key":"jsc260010r132","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s40200-025-01699-1","article-title":"Body composition measurement and diabetes\u2014a new perspective on development of antibodies after SARS-CoV-2 booster vaccination.","volume":"24","author":"Van Baal","year":"2025","journal-title":"J Diabetes Metab Disord"},{"key":"jsc260010r133","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1682119","article-title":"Real-world feasibility of co-administration of RSV, COVID-19, and influenza vaccines in older adults: a VAERS-based analysis.","volume":"16","author":"Wei","year":"2025","journal-title":"Front Pharmacol"},{"issue":"4","key":"jsc260010r134","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.108030","article-title":"Serious adverse events following COVID-19 vaccination: a descriptive case series from a rural healthcare system.","volume":"18","author":"Prabhu","year":"2026","journal-title":"Cureus"},{"key":"jsc260010r135","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2026.100809","article-title":"Active surveillance of adverse events following immunisation in children: pre, during and post COVID-19 pandemic.","volume":"30","author":"Soh","year":"2026","journal-title":"Vaccine X"},{"key":"jsc260010r136","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2026.1778064","article-title":"Comparative immunogenicity of COVID-19 vaccination in pregnant and non-pregnant women: a real-world cohort study.","volume":"14","author":"Aksoy","year":"2026","journal-title":"Front Public Health"},{"issue":"2","key":"jsc260010r137","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1093\/infdis\/jiaf568","article-title":"Safety and immunogenicity of a severe acute respiratory syndrome coronavirus 2 spike subunit vaccine stabilized in the prefusion conformation by a second-generation molecular clamp and evaluated in adults aged 18-55 years: a randomized, double-blind, active comparator, phase I trial.","volume":"233","author":"Chappell","year":"2026","journal-title":"J Infect Dis"},{"key":"jsc260010r138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1728845","article-title":"Possible role of pre-vaccination T-lymphocyte subpopulations in the antibody response to COVID-19 vaccines in children undergoing chemotherapy.","volume":"17","author":"P\u00e9terfia","year":"2026","journal-title":"Front Immunol"},{"issue":"4","key":"jsc260010r139","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/hae.70303","article-title":"Acquired haemophilia A and COVID-19 mRNA vaccine tozinameran: analysis of cases registered in the French pharmacovigilance database.","volume":"32","author":"Laeng","year":"2026","journal-title":"Haemophilia"},{"issue":"5","key":"jsc260010r140","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000047509","article-title":"Comparative analysis of adverse events and flares across COVID-19 vaccine platforms in SLE patients.","volume":"105","author":"Louthrenoo","year":"2026","journal-title":"Medicine (Baltimore)"},{"key":"jsc260010r141","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinpr.2025.100525","article-title":"COVID-19 vaccination in patients at higher risk of anaphylaxis: a safe and pragmatic approach.","volume":"29","author":"Berry","year":"2026","journal-title":"Clin Infect Pract"},{"issue":"3","key":"jsc260010r142","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-070209","article-title":"Immune response to COVID-19 vaccination in children with cancer.","volume":"156","author":"Body","year":"2025","journal-title":"Pediatrics"},{"issue":"1","key":"jsc260010r143","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1080\/14760584.2025.2596676","article-title":"Incidence of stroke following COVID-19 vaccination: a nationwide self-controlled risk interval study in Qatar.","volume":"24","author":"Chemaitelly","year":"2025","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"jsc260010r144","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2026-004112","article-title":"Myocarditis after COVID-19 mRNA vaccination in Norway: a nationwide validation study.","volume":"13","author":"Hagen","year":"2026","journal-title":"Open Heart"},{"issue":"2","key":"jsc260010r145","doi-asserted-by":"publisher","first-page":"123","DOI":"10.21911\/aai.2025.759","article-title":"Impact of co-morbidities on hypersensitivity reactions to COVID-19 vaccines.","volume":"23","author":"Korkmaz","year":"2025","journal-title":"Asthma Allergy Immunol"},{"issue":"12","key":"jsc260010r146","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.cjco.2025.08.006","article-title":"COVID-19 vaccination uptake and myocarditis and\/or pericarditis complications among Chinese and South Asian individuals in Ontario.","volume":"7","author":"Moe","year":"2025","journal-title":"CJC Open"},{"issue":"1","key":"jsc260010r147","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1186\/s12879-025-12023-w","article-title":"Long-term trends in reporting of cardiac adverse drug reactions to COVID-19 vaccines\u2014an exploratory analysis of the EudraVigilance database.","volume":"25","author":"Nazar","year":"2025","journal-title":"BMC Infect Dis"},{"key":"jsc260010r148","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.128016","article-title":"Revaccination of individuals with cardiac adverse events following COVID-19 vaccination: a Canadian Immunization Research Network study.","volume":"70","author":"Pich\u00e9-Renaud","year":"2026","journal-title":"Vaccine"},{"issue":"1","key":"jsc260010r149","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2026.2644030","article-title":"Hematologic adverse events following COVID-19 vaccination and revaccination in persons aged 12 and above: a Canadian Immunization Research Network study.","volume":"22","author":"Smolinski","year":"2026","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"jsc260010r150","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40264-025-01579-w","article-title":"Implementation and results of active vaccine safety monitoring during the COVID-19 pandemic in the UK: a regulatory perspective.","volume":"48","author":"Wong","year":"2025","journal-title":"Drug Saf"},{"key":"jsc260010r151","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1741967","article-title":"Updated profiling of COVID-19 vaccine adverse events using VAERS case reports.","volume":"17","author":"He","year":"2026","journal-title":"Front Pharmacol"},{"issue":"3","key":"jsc260010r152","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2025.106029","article-title":"COVID-19 vaccination and impact on morbidity among nursing home residents, October 2024-January 2025: an ecological analysis.","volume":"27","author":"Khan","year":"2026","journal-title":"J Am Med Dir Assoc"},{"issue":"5","key":"jsc260010r153","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.12609","article-title":"Recent COVID-19 vaccination and risk of SARS-CoV-2 transmission.","volume":"9","author":"Benist","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"6","key":"jsc260010r154","doi-asserted-by":"publisher","first-page":"77","DOI":"10.15585\/mmwr.mm7506a2","article-title":"Respiratory virus activity\u2014United States, July 1, 2024-June 30, 2025.","volume":"75","author":"Silk","year":"2026","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"jsc260010r155","doi-asserted-by":"publisher","DOI":"10.1016\/j.acepjo.2026.100416","article-title":"First responders have lower COVID-19 vaccination rates than other healthcare providers.","volume":"7","author":"Anghelina","year":"2026","journal-title":"J Am Coll Emerg Physicians Open"},{"issue":"6","key":"jsc260010r156","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/15568253261450169","article-title":"Breastfeeding may confer long-term immunity against emerging infectious pathogens\u2014ecological evidence over 2 full years of the COVID-19 epidemic in Georgia, United States.","volume":"21","author":"Chopak-Foss","year":"2026","journal-title":"Breastfeed Med"},{"issue":"11","key":"jsc260010r157","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1097\/INF.0000000000004866","article-title":"Clinical outcomes in children &lt;5 years of age hospitalized for respiratory syncytial virus, COVID-19 or influenza in the United States.","volume":"44","author":"Andersen","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"jsc260010r158","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jhin.2026.02.010","article-title":"Likelihood of SARS-CoV-2 transmission in multi-bedded patient rooms by infecting variant.","volume":"171","author":"Aslam","year":"2026","journal-title":"J Hosp Infect"},{"issue":"7","key":"jsc260010r159","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.23042","article-title":"Children\u2019s birthday gatherings and SARS-CoV-2 infection in grandparents.","volume":"9","author":"Espenhain","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"1","key":"jsc260010r160","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1186\/s12889-025-24260-4","article-title":"Variation in COVID-19 vaccination and adverse outcomes: a state of Georgia case study.","volume":"25","author":"Fujimoto","year":"2025","journal-title":"BMC Public Health"},{"key":"jsc260010r161","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2026.1808528","article-title":"Severe outcomes of individual or multiple respiratory viral infections in a large national healthcare system, 2022-2023.","volume":"14","author":"Grubber","year":"2026","journal-title":"Front Public Health"},{"issue":"5","key":"jsc260010r162","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2025.108227","article-title":"Chronic conditions as risk factors for COVID-19\u2013associated hospitalization among adults, 2020-2023.","volume":"70","author":"Hamid","year":"2026","journal-title":"Am J Prev Med"},{"issue":"6","key":"jsc260010r163","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0330793","article-title":"Long COVID risk by pre-infection symptoms and functional status: a retrospective cohort study of data from the All of Us research program.","volume":"21","author":"Kehl-Floberg","year":"2026","journal-title":"PLoS One"},{"issue":"14","key":"jsc260010r164","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.3201\/eid3114.241982","article-title":"Long-term illness in adults hospitalized for respiratory syncytial virus disease, United States, February 2022-September 2023.","volume":"31","author":"Leis","year":"2025","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"jsc260010r165","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1013723","article-title":"Clinical progression parameters associated with SARS-CoV-2, influenza, and respiratory syncytial virus infections in a large US integrated healthcare population.","volume":"21","author":"Parker","year":"2025","journal-title":"PLOS Comput Biol"},{"issue":"8","key":"jsc260010r166","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3390\/vaccines13080850","article-title":"Impact of vaccination and prior infection on SARS-CoV-2 viral load in preschool children during the Omicron pandemic.","volume":"13","author":"Suzuki","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"9","key":"jsc260010r167","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.31499","article-title":"Clinical testing for COVID-19, influenza, and RSV in hospitalized youths, 2016-2024.","volume":"8","author":"Toepfer","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"6","key":"jsc260010r168","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.amjms.2026.03.001","article-title":"Prevalence and symptoms of post-COVID-19 syndrome in active-duty military personnel.","volume":"371","author":"Cintron","year":"2026","journal-title":"Am J Med Sci"},{"issue":"7","key":"jsc260010r169","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.echo.2026.03.006","article-title":"Ventricular strain and correlation with cardiovascular symptoms and pulmonary function testing in pediatric patients with a history of COVID-19: results from the Pediatric SARS-CoV-2 Long Term Outcomes Study.","volume":"39","author":"He","year":"2026","journal-title":"J Am Soc Echocardiogr"},{"issue":"11","key":"jsc260010r172","doi-asserted-by":"publisher","first-page":"416","DOI":"10.15585\/mmwr.mm7111a4","article-title":"The Advisory Committee on Immunization Practices\u2019 recommendation for use of Moderna COVID-19 vaccine in adults aged =18 years and considerations for extended intervals for administration of primary series doses of mRNA COVID-19 vaccines\u2014United States, February 2022.","volume":"71","author":"Wallace","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"jsc260010r173","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1014169","article-title":"Seasonal forcing and waning immunity drive the sub-annual periodicity of the COVID-19 epidemic.","volume":"22","author":"Rubin","year":"2026","journal-title":"PLoS Pathog"},{"key":"jsc260010r175","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedhc.2026.06.017","article-title":"Neonatal and infant health outcomes following maternal COVID-19 vaccination: CDC\u2019s COVID-19 Vaccine Pregnancy Registry.","author":"Zauche","journal-title":"J Pediatr Health Care"},{"key":"jsc260010r1","unstructured":"World Health Organization. WHO COVID-19 dashboard. Accessed July 20, 2026. https:\/\/data.who.int\/dashboards\/covid19\/deaths"},{"key":"jsc260010r2","unstructured":"Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) Hospitalization Surveillance Network (COVID-NET). Published January 30, 2026. Accessed July 20, 2026. https:\/\/www.cdc.gov\/covid\/php\/covid-net\/index.html"},{"key":"jsc260010r3","unstructured":"Centers for Disease Control and Prevention. 2025-2026 Respiratory disease season outlook evaluation. Published May 4, 2026. Accessed July 20, 2026. https:\/\/www.cdc.gov\/cfa-qualitative-assessments\/php\/data-research\/25-26-outlook-evaluation.html"},{"key":"jsc260010r6","unstructured":"American College of Obstetricians and Gynecologists. COVID-19 vaccination considerations for obstetric-gynecologic care. Published December 2020. Updated March 2026. Accessed July 22, 2026. https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-vaccination-considerations-for-obstetric-gynecologic-care"},{"key":"jsc260010r12","unstructured":"US Food and Drug Administration. Vaccines licensed for use in the United States. Accessed July 20, 2026. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaccines-licensed-use-united-states"},{"key":"jsc260010r13","unstructured":"US Food and Drug Administration. What is a serious adverse event? Accessed August 1, 2026. https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event"},{"key":"jsc260010r128","unstructured":"Obeidat? N, Khasawneh? R, Alrawashdeh? A, . Shoulder injury related to vaccine administration following COVID-19 vaccination: insights from a cross-sectional study in Northern Jordan. Bahrain Medical Bulletin. Accessed August 20, 2026. https:\/\/www.bahrainmedicalbulletin.com\/March2026\/BMB-25-1156.pdf"},{"key":"jsc260010r170","unstructured":"US Food and Drug Administration. CBER Biologics Effectiveness and Safety (BEST) system. Accessed August 10, 2026. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/cber-biologics-effectiveness-and-safety-best-system"},{"key":"jsc260010r171","unstructured":"Tworkoski? E, Wong? HL, Zhou? CK, . Master protocol: assessment of risk of safety outcomes following COVID-19 vaccination. US Food and Drug Administration. Published May 28, 2021. Accessed August 10, 2026. https:\/\/www.fda.gov\/media\/193192\/download?attachment"},{"key":"jsc260010r174","unstructured":"World Health Organization. Statement on the antigen composition of COVID-19 vaccines. Published May 16, 2026. Accessed August 10, 2026. https:\/\/www.who.int\/news\/item\/16-05-2026-statement-on-the-antigen-composition-of-covid-19-vaccines"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2853778\/jama_lipson_2026_sc_260010_1790364336.4185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:03:30Z","timestamp":1790694210000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2853778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":175,"URL":"https:\/\/doi.org\/10.1001\/jama.2026.18191","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}